Medical network - January 10, 2016 is the "dividend policy" of traditional Chinese medicine, the law of the People's Republic of China law of Chinese medicine in 2016 at the end of the formal introduction; The "healthy China 2030" planning outline as the next 15 years to promote health and an action plan for China's construction, put forward a series of revitalization of the development of Chinese medicine, health service tasks and measures of the construction of the Chinese; The strategic plan for development of Chinese medicine (2016-2030), "the development of traditional Chinese medicine rise for the national strategy, to promote the development of Chinese medicine in the new period system deployment. In addition, the development of traditional Chinese medicine "much starker choices-and graver consequences-in planning", the white paper on "China's traditional Chinese medicine" and a series of blockbuster file has released, make traditional Chinese medicine industry is quietly changing, the profound change, probably is based in the next few years market pattern of traditional Chinese medicine.
Dividend policy using
1, the method of traditional Chinese medicine
On December 25, the method of traditional Chinese medicine of the People's Republic of China formally launched, this is China's first dedicated to the law of traditional Chinese medicine. Method of traditional Chinese medicine is divided into "Chinese medicine service" "the protection and development of traditional Chinese medicine (TCM)", "Chinese medicine personnel training" "scientific research of traditional Chinese medicine" "heritage and cultural dissemination of traditional Chinese medicine" "safeguard measures" "legal liability", chapter 9, article 63, will come into force as of July 1, 2017.
Those remarks
The law has been clear about the important status and the development of the undertaking of traditional Chinese medicine principle, put forward the "cause of traditional Chinese medicine is an important part of medicine and health care in China. Countries to develop the cause of Chinese medicine, implement the policy of paying equal attention to" Chinese and western medicine. "Development enterprise shall abide by the law of development of traditional Chinese medicine of traditional Chinese medicine, adhere to the combination of inheritance and innovation, maintain and developing the characteristic and the superiority of TCM". "The state encourages the western medicine of traditional Chinese medicine learn from each other, complement each other, coordinated development, give play to their respective advantages, promote the combination of Chinese and western medicine", to inherit and carry forward the traditional Chinese medicine, promote the healthy development of the cause of Chinese medicine to provide powerful legal support.
2, the white paper on "China's traditional Chinese medicine"
On December 6, the state council information office released white paper on "China's traditional Chinese medicine", this is a white paper published for the first time in our country development of traditional Chinese medicine. White paper from the history of medicine development and characteristics of national policies, the development of Chinese medicine in China and the main measures, the heritage and development of traditional Chinese medicine, Chinese medicine international exchange and cooperation, and so on has carried on the outline to our country the development of TCM.
Those remarks
The paper systematically summarizes the thread of the development of Chinese medicine, and embodies the Chinese medicine "cure not ill", emphasis on individual, "Jane, then, check-up, cheap", etc. Released a white paper, it shows that the country's attitude toward traditional Chinese medicine, the traditional Chinese medicine and western medicine in the equally important position, will rise for the national strategic development of Chinese medicine.
3, "" much starker choices-and graver consequences-in planning development of Chinese medicine"
On August 11, the state administration of traditional Chinese medicine officially issued by the development of traditional Chinese medicine "much starker choices-and graver consequences-in planning", aims to promote the revitalization of the development of Chinese medicine, better for the construction of health service in China.
Those remarks
"Planning" clearly put forward the development of domestic industry of Chinese medicine, by 2020, everyone enjoys the basic services of traditional Chinese medicine, set up perfect medical service system of traditional Chinese medicine. Embodies in five dimensions: the people obtain the accessibility of health service of traditional Chinese medicine significantly enhanced, supporting system more robust development of Chinese medicine, Chinese medicine health industry rapid development, more inclusive open development of Chinese medicine, Chinese medicine management system and management ability of modern rapid advance.
4, on the cancellation of Chinese herbal medicine production quality management standard certification announcement
On March 18th, the CFDA website "for Chinese herbal medicine production quality management standard certification related matters announcement no. 72 (2016).
Those remarks
In fact, in printed and distributed by the state council "about cancel 13 departments under the state council the decision of the administrative licensing items" (guo fa [2016] no. 10), has offered to cancel the Chinese herbal medicine production quality management standard certification (GAP). But note that countries cancel GAP certification doesn't mean the Chinese herbal medicine planting without GAP management, the country will strengthen the management of Chinese medicinal materials, from the aspects of roots or through third parties such as industry association to certification. And already through the authentication of Chinese herbal medicine production enterprises should continue according to the regulations of the Chinese herbal medicine GAP, strengthen the whole process of quality management, to ensure continued compliance. Are the source of traditional Chinese medicine main channel GAP base, including species, breeding base, as the administrative main body by the enterprise, the government department will check according to the need for the extension type, as to not species, breeding of wild medicinal herbs can be purchased, but origin relatively fixed.
5, the strategic plan for development of Chinese medicine (2016-2030)"
On February 26, the state council released the strategic plan for development of Chinese medicine (2016-2030), puts forward seven aspects of 24 key tasks.
Those remarks
The outline is the April 2009 issued the several opinions about support and promote the development of Chinese medicine, nearly seven years later, another is traditional Chinese medicine under the state council work to conduct a comprehensive deployment. The outline put forward two milestones: by 2020, realize everyone enjoys the basic services of traditional Chinese medicine, the public hospital 0.55 beds per thousand population, per thousand population health institutions of traditional Chinese medicine professional class (assistant) 0.4 doctors, Chinese medicine gross value of industrial output by more than 30% of the total output value of pharmaceutical industry, medicine industry become one of the important pillar of the national economy; By 2030, complete coverage of services implementation of traditional Chinese medicine, Chinese medicine will markedly enhance its capability of health services, to the guarantee of economic and social development and people's health more evident contribution.
Five trends in the future
1, the medicinal material price to rise into the channel
Reflect on the performance of the domestic Chinese market overall comprehensive index of 200, has been from the beginning of December 7, 2215.36 points to 2549.19 points, or 15%. In addition to the composite index, part of traditional Chinese medicinal materials prices rose sharply. Traditional Chinese medicinal materials of heaven and earth, according to data from the network evodia rutaecarpa (jiangxi floret system specifications, the lotus pond market) the year up 372.73%; Notoginseng (seven specifications, the spring of 120 in yunnan pond market) the year up 170%; Atractylodes (anhui system specifications, yulin market) the annual increase of 115.38%. Otherwise, according to data in the year to October, Chinese angelica, codonopsis, fructus schisandrae the main medicine price year-on-year increase of 37.7%, 99.5% and 103.6%, respectively. This year, in fact, in addition to the medicinal materials, most of the Chinese herbal medicine showed a trend of rising, including small varieties of medicinal materials also rose sharply.
Those remarks
Experts in the near future for Chinese traditional medicine prices, said "appropriate to adjust the prices of Chinese herbal medicine is a must, is the development of important aspects for the sustainable development of traditional Chinese medicine; the government will vigorously promote the standardization of the Chinese herbal medicine planting, on the one hand to form scale, ensure supply, on the other hand to establish a reasonable price adjustment mechanism."
From the point of the present domestic a piece of Chinese herbal medicine planting enthusiasm, over the next two years will be a great year of Chinese herbal medicine production. Though prices have continued to rise of domestic drug market space, but the huge risk of inventory and production expansion is brewing. Traditional Chinese medicine before heaven and earth net is expected in July 2017, drug market may be a turning point, suggested the industry for a rainy day.
2, more herbs will into Europe and the United States pharmacopoeia
As of May 2016, our country has 2016 kinds of Chinese herbal medicine to enter the European pharmacopoeia, the future of traditional Chinese medicine (TCM) aims to the most commonly used at least 300 kinds of Chinese medicinal materials incorporated in the European pharmacopoeia.
Those remarks
Now has entered the Chinese medicinal materials including ginseng, dried tangerine or orange peel of the European pharmacopoeia, atractylodes, rhubarb, pink flower, giant knotweed, notoginseng, etc. 66 kinds of Europe more than a third of the number 184 kinds of herbs in pharmacopoeia. In addition to the European pharmacopoeia, some Chinese traditional medicine has been listed in the United States pharmacopoeia standard, there are also some drugs are a review by the United States pharmacopoeia committee. For example, fructus schisandrae, coix seed, cassia twig, red ginseng, honeysuckle, fleece-flower root, salvia miltiorrhiza, notoginseng, ganoderma lucidum herbal standard such as traditional Chinese medicine has been the United States pharmacopoeia (included, salvia miltiorrhiza, notoginseng, ganoderma lucidum three volume into food supplements at the same time.
Varieties of traditional Chinese medicines were collected, and the future in terms of safety, quality, curative effect with Europe and the United States recognized standards, in a foreign country for traditional Chinese medicine is more widely accepted use foundation, also is the first step on the Chinese medicine medicine open export channels.
3, Chinese medicine yinpian quality scrutiny
On May 24, the state administration of traditional Chinese medicine issued the national Chinese medicine yinpian management special inspection scheme of medical institution "notice, to hunt down the quality of the Chinese medicine yinpian. At the same time, the provincial drug quality report, published in succession, substandard drugs are often visible Chinese medicine yinpian inside. Chinese medicine yinpian enterprise fly has become the focus of the object.
Those remarks
On the one hand, since 2016, numerous provinces key regulatory directory by Chinese medicine yinpian, visible in traditional Chinese medicinal materials quality inspection and tracking has become the norm. Future for Chinese herbal medicine regulation will be more violent, will promote the growth of the Chinese medicine yinpian industry towards more quality.
The national level, on the other hand, attaches great importance to and promote the development of Chinese medicine yinpian market is good. Adhere to the quality of operation, has the marketing network of enterprises will be the winner of the market.
4, formula particles increased competition
The CFDA website "measures for the management of traditional Chinese medicine formula particles (draft)" on March 1, 2016, in globe for advice.
Those remarks
Since the "measures for the administration of traditional Chinese medicine formula particles (draft) is released, the strategic plan for development of Chinese medicine (2016-2030)," the traditional Chinese medicine formula particles into the "much starker choices-and graver consequences-in" plan; National pharmacopoeia committee issued "the traditional Chinese medicine formula particles quality control standards and technical requirements (draft)" in early November by the feedback collection, will release the industry from the pilot to formal production, the market gradually open positive signal. Pilot enterprises for the future, weak competition and relative monopoly will be broken, formula particles or will intensify competition.
5, proprietary Chinese medicine whole
Influenced by traditional Chinese medicine injection stagnation and regulation of traditional Chinese medicine raw materials etc, proprietary Chinese medicine will slow its growth in 2016, is expected to be 4.9%. Forward-looking industry research analysis, from the point of Chinese medicines, 66 listed companies data report, is the overall growth rate of 10%, net profit growth there are as many as 18 companies, including five corporate revenue, net profit both negative growth.
Those remarks
Industry as a whole situation is not optimistic but as a series of new policies, proprietary Chinese medicine industry in dividend policy to promote the development of The Times. CFDA south medicine economic research institute, predicts that "much starker choices-and graver consequences-in" Chinese medicine industrial scale will be doubled. By 2020, the scale of Chinese medicine industry business owners the business income is 1.5823 trillion yuan.
National policy support for secondary development of traditional Chinese medicine (TCM) : there are more than 270 $at present Chinese medicine great varieties, 50% of the total sales is now Chinese medicine market. National 12th five-year plan clearly put forward science and technology, in the next five years to focus on support and in 30 second development of varieties of traditional Chinese medicine. There are 24 listed in "much starker choices-and graver consequences-in" creating a significant innovation of new drug of TCM medicine. Traditional Chinese medicine industry in the next five years will be into the policy of good innovation brought by the development. |
